Core Insights - 20/20 BioLabs is advancing its patented protein tumor marker (PTM) based, machine learning derived multi-cancer early detection (MCED) methodology, which shows promise for earlier stage cancer detection compared to circulating tumor DNA (ctDNA) based methods [1][4][5] Group 1: MCED Methodology and Findings - Recent studies indicate that protein biomarkers may effectively identify early-stage cancers, addressing the limitations of ctDNA tests, which often fail to detect cancer until it has progressed [3][4] - A large-scale ctDNA-based MCED study in the U.K. has highlighted the biological constraints of ctDNA as a first-line screening tool for early-stage cancers, emphasizing the need for alternative approaches [2][4] - 20/20 BioLabs' OneTest for Cancer has demonstrated detection rates for early-stage cancers as high as 50% for certain tumor types, such as pancreatic and ovarian cancers, in asymptomatic populations [6] Group 2: Validation and Support for Protein Biomarkers - A multicenter validation study published in Nature's Precision Oncology showed consistent cancer signal detection across diverse populations, with measurable sensitivity even in Stage I disease [6] - A blinded validation study at MD Anderson Cancer Center reported that a protein-based multicancer test identified nearly 90% of early-stage lung cancers, indicating the effectiveness of protein tumor markers during early oncogenesis [6] Group 3: Strategic Approach and Future Directions - The company proposes a tiered approach to cancer screening, where protein-based tests like OneTest serve as the initial screening step, followed by ctDNA testing for individuals identified at mild risk [7] - The recent legislation passed by Congress to create a pathway for Medicare coverage of MCEDs starting in 2028 is seen as a significant advancement for cancer screening access [8] - 20/20 BioLabs is committed to building the evidence base for protein-based technologies and working with policymakers to ensure effective screening tools are available [8]

Burning Rock Biotech Limited 4Q 2025 results 12 March 2026 Disclaimer This presentation has been prepared by Burning Rock Biotech Limited (the "Company") solely for information purpose and has not been independently verified. No representations, warranties or undertakings, express or implied, are made by the Company or any of its affiliates, advisers, or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness or correctness of the information or opinions presented ...

Core Viewpoint - Hims & Hers Health, Inc. has launched the Hims & Hers Multi-Cancer Test by Galleri®, a blood test capable of detecting signals for over 50 types of cancer before symptoms appear, aiming to enhance access to proactive cancer care [1][2]. Group 1: Product Launch and Features - The Multi-Cancer Test by Galleri® can detect signals for more than 50 types of cancer, including those without recommended screenings, and is designed to be taken annually [2][3]. - The test leverages GRAIL's innovative technology to improve early detection of cancer signals in blood, predicting the likely origin of the signal in the body [3][4]. Group 2: Market Context and Importance - Over one in three individuals will develop cancer in their lifetime, with many cancers remaining undetected until later stages, which complicates treatment and worsens outcomes [1][2]. - The introduction of the Galleri test aims to address the gap in early cancer detection, particularly for aggressive cancers that are often diagnosed late [1][4]. Group 3: Pricing and Accessibility - Starting today, Hims & Hers customers can access the Multi-Cancer Test by Galleri® at a $250 discount from the list price, making it more affordable [5].